Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
32.57
+0.22 (0.68%)
Nov 6, 2025, 4:00 PM EST - Market closed
Korro Bio Revenue
Korro Bio had revenue of $1.46M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $6.28M. In the year 2024, Korro Bio had annual revenue of $2.27M.
Revenue (ttm)
$6.28M
Revenue Growth
n/a
P/S Ratio
48.55
Revenue / Employee
$60,394
Employees
104
Market Cap
305.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.27M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKRRO News
- 2 months ago - Korro to Participate in Upcoming Investor and Scientific Conferences - GlobeNewsWire
- 3 months ago - Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 - GlobeNewsWire
- 6 months ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - GlobeNewsWire
- 8 months ago - Korro Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 8 months ago - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire